Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
12.88
+0.23 (1.82%)
Apr 8, 2026, 3:04 PM CST
Market Cap20.23B +4.3%
Revenue (ttm)2.42B -14.3%
Net Income177.74M +25.0%
EPS0.11 +25.0%
Shares Out1.60B
PE Ratio113.86
Forward PE74.41
Dividend0.16 (1.23%)
Ex-Dividend DateJan 9, 2026
Volume55,218,002
Average Volume43,267,855
Open12.80
Previous Close12.65
Day's Range12.45 - 12.97
52-Week Range9.70 - 14.65
Beta0.47
RSI56.27
Earnings DateMar 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis c... [Read more]

Sector Healthcare
Founded 2001
Employees 1,981
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2025, Walvax Biotechnology's revenue was 2.42 billion, a decrease of -14.29% compared to the previous year's 2.82 billion. Earnings were 177.74 million, an increase of 25.03%.

Financial Statements